Whole-cell recordings and viral retrograde tracing in rats show that the interstitial nucleus of Cajal responds to ...
Laboratory electrophysiology, molecular simulations and mutational analysis identify an intersubunit transmembrane site ...
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration ...
<?xml encoding="utf-8" ?> The U.S. Food and Drug Administration (FDA) on Friday approved the first self-administered, once-daily, autoinjector administration option of UCB SA’s UCBJY UCBJF Zilbrysq ...
Clinically approved drugs induced ChAT expression and acetylcholine production in podocytes in vivo, suggesting the pathway could be pharmacologically targeted.
Two people who watch the same movie may remember completely different scenes.One person remembers the words spoken by the ...
Exploratory phase 3 data suggest that gefurulimab may reduce the need for rescue therapy and hospitalizations in patients ...
The new research, published in ERJ Open Research, found that nearly one in five asthma patients and one in three COPD ...
Clinical Trials Arena on MSN
Vanda puts anxiety drug’s development on ice after Phase III fail
This comes as many pharma companies fail to crack the SAD indication, with little innovation seen in the space in recent ...
China NMPA approves Harbour BioMed’s BLA for batoclimab injection to treat generalized myasthenia gravis: Cambridge, Massachusetts Saturday, October 24, 2026, 17:00 Hrs [IST] Ha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results